We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 22, 2020

Outcomes of CKD4/6 Inhibitors Continued Beyond First Disease Progression in HR+ Metastatic Breast Cancer

Clinical Breast Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Breast Cancer
Real-World Outcomes of Cyclin-Dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-Positive Metastatic Breast Cancer
Clin. Breast Cancer 2020 Oct 02;[EPub Ahead of Print], AS Eziokwu, L Varella, ML Kruse, X Jia, HCF Moore, GT Budd, J Abraham, AJ Montero

Further Reading